Cipla Ltd has announced that a routine current Good Manufacturing Practices (cGMP) inspection was conducted by the United States Food and Drug Administration (USFDA) at manufacturing facility of the company located in Kurkumbh, Maharashtra, India from 29th April, 2024 to 8th May, 2024.

On conclusion of the inspection, the company has received 1 inspectional observation in Form 483. The company will work closely with the USFDA and is committed to address this observation comprehensively within stipulated time.